European Ophthalmic Pathology Society

Azura Ophthalmics Presents Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunction at Ophthalmology Innovation Summit XII

Retrieved on: 
Friday, December 9, 2022
Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Biotechnology, Therapy, Baozou Big News Events, M. B, Exocrine gland, Selenium disulfide, Military medicine, Veteran, Diagnosis, Visual Science, Corneal ulcers in animals, Patient, Duane syndrome, Classification, Milner, MGS, OIS, Total, M. A, Drug development, Meibomian gland, News, MGD, European Ophthalmic Pathology Society, All rights reserved, Adverse Events, Luchs, Safety, Investigative Ophthalmology & Visual Science, Systematic review, Contact lens, AES, Prevalence, Pharmaceutical industry, Telescopic sight, Medical device, OSDI, Ophthalmology, Azura, Amit Majmudar

It was a pleasure to share our exciting Phase 2b results at OIS XII, and we look forward to advancing AZR-MD-001 to a pivotal Phase 3 clinical trial for MGD in 2023.

Key Points: 
  • It was a pleasure to share our exciting Phase 2b results at OIS XII, and we look forward to advancing AZR-MD-001 to a pivotal Phase 3 clinical trial for MGD in 2023.
  • The results from Azuras Phase 2b study of AZR-MD-001 0.5% in MGD were presented during the Spotlight on Dry Eye session at OIS XII.
  • The Phase 2b trial was a multi-center, double-masked, vehicle-controlled, parallel group study that evaluated the safety and efficacy of AZR-MD-001 in 245 patients with MGD.
  • Meibomian Gland Dysfunction is a chronic and progressive condition associated with blockage of the meibomian glands and alteration in the quality of expressed meibum which can end in gland atrophy.

Azura Ophthalmics Announces Participation at Upcoming Investor Conferences

Retrieved on: 
Monday, November 21, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, M. B, Duane syndrome, Selenium disulfide, Contact lens, Luchs, Exocrine gland, M. A, Drug development, Corneal ulcers in animals, Conference, Classification, Safety, Piper Sandler Companies, Therapy, Meibomian gland, Milner, European Ophthalmic Pathology Society, MGD, Diagnosis, Patient, Medical device, Telescopic sight, Pharmaceutical industry, Ophthalmology, Amit Majmudar, Azura

The Azura management team will also be available for 1X1 investor meetings.

Key Points: 
  • The Azura management team will also be available for 1X1 investor meetings.
  • AZR-MD-001 is currently being studied to evaluate the safety, efficacy, and tolerability of the study drug in patients with MGD.
  • Azura expects to initiate a second pivotal multi-center clinical trial of AZR-MD-001 0.5% in 2023.
  • Azura Ophthalmics is utilizing our deep understanding of ocular surface diseases and drug development to deliver a new therapeutic class of Ophthalmic Keratolytics to treat underserved ophthalmic conditions.

Azura Ophthalmics Announces Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunction

Retrieved on: 
Thursday, November 17, 2022
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Total, Medical director, M. A, Irritation, Exocrine gland, MGS, Safety, Investigative Ophthalmology & Visual Science, Meibomian gland, European Ophthalmic Pathology Society, Veteran, MGD, AES, LASIK, United, Drug development, VAS, All rights reserved, Eyelid, Physician, Pain, Diagnosis, Patient, Duane syndrome, Prevalence, Selenium disulfide, Luchs, Corneal ulcers in animals, Classification, Gland, Military medicine, Therapy, Milner, SPEED, Business, M. B, Systematic review, Adverse Events, Contact lens, Warrenville, Pharmaceutical industry, Medical imaging, Telescopic sight, Medical device, OSDI, Ophthalmology, Amit Majmudar, Azura

Azura Ophthalmics Ltd. , a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced positive 3-month efficacy and safety results from its Phase 2b study of AZR-MD-001 0.5% in Meibomian Gland Dysfunction (MGD).

Key Points: 
  • Azura Ophthalmics Ltd. , a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced positive 3-month efficacy and safety results from its Phase 2b study of AZR-MD-001 0.5% in Meibomian Gland Dysfunction (MGD).
  • We are thrilled to build upon these positive results by advancing AZR-MD-001 to a pivotal Phase 3 clinical trial for MGD in 2023.
  • I look forward to collaborating with the Azura team and my fellow scientific advisory board members to advance AZR-MD-001.
  • Meibomian Gland Dysfunction is a chronic and progressive condition associated with blockage of the meibomian glands and alteration in the quality of expressed meibum which can end in gland atrophy.

Nicox Announces a New Governance Structure

Retrieved on: 
Monday, May 16, 2022
Kepler, Sanofi, University, Board of directors, D-Company, Duane syndrome, Euronext Paris, European Ophthalmic Pathology Society, HEC, LLC, University Hall (Uppsala University), Master of Science, Andreas, Investment, Allergic conjunctivitis, Therapy, Audit committee, NCX, Organic chemistry, Latanoprost, Board, Ocular hypertension, Founder, Business, Royal institute, Company, Director, COX, Pharmacia, Johannes Kepler, Pharma, HMR, KTH Royal Institute of Technology, MBA, R, Bausch & Lomb, Leadership, Patient, Compartment, Intraocular pressure, Institute of International Finance, Roussel Uclaf, Marketing, Fluticasone, Pharmacia & Upjohn, Glaucoma, Management, Pharmaceutical industry, Fine chemical, Ophthalmology, NicOx

Michele Garufi will remain as Board member of Nicox SA.

Key Points: 
  • Michele Garufi will remain as Board member of Nicox SA.
  • Jean-Franois Labb has served as a member of Nicox Board of Directors since 2010 and has been the Chairman of the Audit Committee of Nicox since 2013.
  • Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health.
  • Nicox disavows any obligation to correct or to update the information contained in analyst reports.